Methods of treating disorders associated with protein polymerization
The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine, oxcarbazepine or another carbamazepine-like compound. It is based, at least in part, on the discovery that, in cells having a genetic defect in α1-antitrypsin, carbamazepine was able to decrease levels of the mutant protein. Furthermore, carbamazepine reduced the hepatic load of mutant α1-antitrypsin and the toxic effect of that mutant protein accumulation, hepatic fibrosis, in vivo using a mouse model of the disease. As patients having this defect in α1-antitrypsin exhibit toxic accumulations of the protein, treatment according to the invention may be used to ameliorate symptoms and signs of disease.
1. A method of treating a subject suffering from α1-antitrypsin deficiency comprising administering, to the subject, an effective amount of oxcarbazepine.
2. A method of treating α1-antitrypsin deficiency comprising administering, to a subject in need of such treatment, an effective amount of carbamazepine.